Open House Biologics Discount Agreement for Epoetin Alfa and Epoetin Zeta
Originaltitel der Bekanntmachung
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 12 Epoetin alfa und Epoetin zeta
Opportunity Score
Warum diese Bewertung?
Chance
62 / 100
Komplexität
58 / 100
Risikofaktoren
The notice says offers/contracts cannot be submitted via the procurement portal; they must be sent by email with qualif...
Only pharmaceutical companies meeting the AMG and market authorisation requirements for the specific medicines appear e...
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Überblick
Moderate opportunityWichtige Fakten
- Supplies contract
- 1 lot
- Duration until Jun 2028
- Open House conclusion of pharmaceutical discount agreements under Section 130a(8) SGB V for Epoetin alfa and Epoetin zeta.
- Nationwide supply/performance in Germany.
Vollständige Zusammenfassung anzeigen
Open House procedure by Techniker Krankenkasse for non-exclusive discount agreements on pharmaceutical products for Epoetin alfa and Epoetin zeta (CPV 33600000). The notice states that all suitable pharmaceutical companies may join during the contract period, with uniform conditions and no individual negotiation. The contract term is up to 24 months from 01/07/2026 to 30/06/2028. No contract value is stated in the provided data. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the procedure communication is via the TK portal communication area/email. Procurement documents are available online, but only the notice text was provided for analysis.
Risiken
The notice says offers/contracts cannot be submitted via the procurement portal; they must be sent by email with qualif...
Only pharmaceutical companies meeting the AMG and market authorisation requirements for the specific medicines appear e...
Analyse kann unvollständig sein
Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.
Wichtige Anforderungen
Technical
- Applicant must be a pharmaceutical company within the meaning of Section 4(18) AMG for the relevant medicines.
- Applicant must have its seat in Germany, another EU Member State, or another EEA state.
- Applicant must hold a valid marketing authorisation for the medicines and/or otherwise be entitled to place them on the market in its own name.
Zuschlagskriterien
Lot 1
Auftraggeber
Ort
Hamburg, DEU
Website
Kennung
992-80116-93
Tätigkeit
Health
Lose (1)
LOT-0001
Open House Biologics Discount Agreement for Epoetin Alfa and Epoetin Zeta
Lot 1 concerns an Open House discount agreement for the medicinal products Epoetin alfa and Epoetin zeta. Scope is nationwide in Germany. The notice indicates open accession for all eligible pharmaceutical companies, no exclusivity, and no individual negotiation. The lot details come from structured data and notice text.
Ort
Dauer
Kategorie
Zuschlagskriterien
Frist
Zuschlagsdetails
The notice states that the award criterion field is irrelevant in this Open House procedure and is included only due to the mandatory form.
Hinweis zum Wert
Originale TED-Daten anzeigen
Originaler Los-Titel
Open House Biologika Rabattverträge 2026 - 12 Epoetin alfa und Epoetin zeta
Originale TED-Beschreibung
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu Epoetin alfa und Epoetin zeta zu schließen.
Vergabedetails
- Veröffentlichungsdatum
- 07 May 2026
- Sprachen
- German
Referenzmetadaten
- Rechtsgrundlage
- 32014L0024
Referenz-IDs
- Ausschreibungs-ID
- 317941-2026
Dokumente (1)
Ähnliche Ausschreibungen
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Warum diese Bewertung?
Chance
62 / 100
Komplexität
58 / 100
Risikofaktoren
The notice says offers/contracts cannot be submitted via the procurement portal; they must be sent by email with qualif...
Only pharmaceutical companies meeting the AMG and market authorisation requirements for the specific medicines appear e...
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications